Investigation follows the November 9, 2026 disclosure regarding LifeMD, Inc.; investors who lost money may have claims to recover their losses

Investors who lost money on LifeMD, Inc. ("LifeMD" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of LifeMD, Inc. (NASDAQ: LFMD) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 9, 2026 disclosure regarding LifeMD, Inc.

Investors who lost money on LifeMD, Inc. securities can submit their LifeMD, Inc. loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the LifeMD, Inc. investigation

• Disclosure date: November 9, 2026
• Stock price decline: $0.35 per share, or 14.56%

What happened?

On November 9, 2026, LifeMD admitted in its Form NT 10-Q that it needed to correct the “over recognition of revenue and under recognition of cost of revenue and general and administrative expenses” in historical financial statements covering 2024 through June 30, 2026.

On this news, LifeMD stock fell as much as $0.35 or 14.56%, during intraday trading on November 9, 2026, thereby injuring investors.

"The price of LifeMD, Inc. shares fell 14.56% following the November 9, 2026 disclosure that LifeMD needed to correct its historical financial statements covering 2024 through June 30, 2026 due to over recognition of revenue and under recognition of cost of revenue and general and administrative expenses. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of LifeMD, Inc. investors. Investors who lost money can contact Glancy about the LifeMD, Inc. investigation, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought LifeMD, Inc. securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the LifeMD, Inc. investigation.

What is a securities fraud investigation? In the LifeMD, Inc. investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against LifeMD, Inc., investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents LifeMD, Inc. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the LifeMD, Inc. investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the LifeMD, Inc. investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about LifeMD, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email shareholders@glancylaw.com.

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

• LifeMD, Inc. investigation page, Glancy Prongay Wolke & Rotter LLP
• LifeMD Form NT 10-Q
• LifeMD, Inc. SEC filings index, EDGAR
• SEC Whistleblower Program
• Glancy Prongay Wolke & Rotter LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110021694/en/